Business context and reporting period
Issuer discrepancy: The request identifies CalciMedica, Inc., but the supplied Form 10-Q is for Graybug Vision, Inc. This summary reflects the filing provided, for the quarter and six months ended June 30, 2022.
Graybug was a clinical-stage biopharmaceutical company developing treatments for eye diseases, with no approved products or product revenue. On June 28, 2022, it announced a review of strategic alternatives, including a sale, merger, asset divestiture, financing, or other transaction. In an August 11, 2022 update, it said clinical development of GB-102, GB-401, and GB-501 was on hold to conserve cash pending that review.
Financial performance and position
Amounts below are in U.S. dollars; financial statement amounts are rounded to millions.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $4.1m | $4.2m | $10.1m | $10.6m |
| General and administrative expense | $4.2m | $3.6m | $8.4m | $8.6m |
| Total operating expenses | $8.3m | $7.7m | $18.5m | $19.2m |
| Net loss | $8.2m | $7.7m | $18.4m | $19.2m |
| Net loss per share, basic and diluted | $0.38 | $0.36 | $0.86 | $0.91 |
| Cash used in operating activities | Not separately provided | Not separately provided | $10.7m | $17.0m |
At June 30, 2022, cash and cash equivalents were $13.9m and short-term investments were $36.8m, totaling $50.7m in cash, cash equivalents, and short-term investments. Current assets were $51.7m and current liabilities $4.3m; total liabilities were $4.3m, with no debt reported. Accumulated deficit was $187.6m and stockholders’ equity was $49.7m. No meaningful operating margin is available because the company reported no revenue.
Changes versus the prior comparable period
- Q2 operating expenses rose 7% year over year, mainly as general and administrative expense increased 19%; R&D expense declined 3%. Q2 net loss increased from $7.7m to $8.2m.
- For the first half, operating expenses decreased 4% and net loss improved from $19.2m to $18.4m. The R&D decrease reflected lower clinical and personnel costs, partly offset by a $2.2m RainBio in-process research and development charge.
- First-half operating cash use declined to $10.7m from $17.0m. Cash and cash equivalents increased $0.5m, while short-term investments declined to $36.8m from $50.3m at year-end 2021, primarily reflecting investment maturities and purchases.
Outlook, risks, and unusual items
- Management estimated that available cash, cash equivalents, and short-term investments would fund operations into the fourth quarter of 2023, based on its then-current plan. The filing also says the company expected to need additional financing to advance programs and operate, and warns that the runway estimate depends on assumptions and could prove shorter.
- The strategic review had no assured outcome. The company warned that if it could not complete a transaction, obtain financing, or reduce spending, it might have to delay, scale back, or discontinue programs or operations; it also disclosed the possibility of a wind-down and liquidation.
- RainBio was acquired in March 2022 for approximately $2.2m, recorded as R&D expense. Additional contingent payments of up to $17.5m may be due upon specified milestones; none were considered probable or recorded at June 30.
- Contractual commitments to research, manufacturing, and other vendors were approximately $3.2m, generally due within three to nine months and generally terminable on 60–90 days’ notice. The company reported $0.4m of operating lease liabilities.
- GB-102’s Phase 2b results included durability signals, but the company disclosed lower average visual-acuity results versus the active comparator and prior dose-related safety events, including medication observed in the anterior chamber. It had not initiated a Phase 3 trial, and further development depended on funding or a strategic partner.
- Nasdaq notified the company of a minimum-bid-price deficiency in June; on July 21, 2022, it reported regaining compliance. Continued listing remained subject to ongoing requirements.
- Management stated disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter. No material legal proceedings were reported.
Investor verification priorities
- Confirm the issuer: the supplied filing is Graybug Vision, Inc., not CalciMedica, Inc.
- Review subsequent filings and announcements for the strategic review’s outcome, the clinical holds, and any change to the cash runway or operating plan.
- Verify current cash, investment liquidity and maturities, spending rate, vendor commitments, and whether additional capital was raised or required.
- Assess whether any RainBio contingent milestones became payable and whether other contractual or transaction costs arose.
- Check current Nasdaq listing status and any later developments affecting shares outstanding, dilution, or potential liquidation proceeds.